Filing Flows › Astera Labs (ALAB) › Takeover & LBO
Is Astera Labs (ALAB) a takeover target?
A leveraged buyout at today's price plus 30% ($336.31 a share) would return a loss of about 4% a year to a private-equity buyer over 5 years; no price, however low, gets a buyer to 20%. At $60.5B it would be larger than any buyout on record (the model flags anything over $60 billion), so this is a thought experiment more than a prospect. Historically 2.1% of companies with its figures were bought within a year (0.42× the average).
The buyout, step by step
| Entry | Amount | How |
|---|---|---|
| Offer price a share | $336.31 | today's $258.70 plus 30% |
| × shares | 184.1 million | |
| = Equity value | $61.9B | |
| + Debt refinanced | $0 | |
| − Cash | $1.4B | |
| = Enterprise value | $60.5B | 146.7× EBITDA of $413M |
| Fees | $1.2B | 2% of the price |
| New debt | $2.3B | 5.5× EBITDA at 7.65% a year; the limit that binds: 5.5× EBITDA |
| Buyer's own money | $59.5B | 96% of the cost |
5 years under the buyer
| Year | Revenue | EBITDA | Interest | Free cash flow | Debt left |
|---|---|---|---|---|---|
| Year 1 | $1.6B | $417M | $174M | $121M | $2.1B |
| Year 2 | $1.6B | $424M | $164M | $133M | $2.0B |
| Year 3 | $1.6B | $433M | $154M | $147M | $1.9B |
| Year 4 | $1.7B | $444M | $143M | $164M | $1.7B |
| Year 5 | $1.7B | $457M | $130M | $183M | $1.5B |
The exit and the buyer's return
| Exit | Amount | |
|---|---|---|
| Exit multiple | 112.1× EBITDA | today's trading multiple, before any premium |
| Enterprise value at exit | $51.2B | |
| − Debt left | $1.5B | |
| = Buyer's equity | $49.7B | |
| Money multiple | 0.84× | on $59.5B put in |
| Buyer's yearly return (IRR) | −3.5% |
Price against return
What the buyer makes at other premiums over today's $258.70.
| Premium | Price a share | Buyer's IRR |
|---|---|---|
| 10% | $284.57 | 0.0% |
| 20% | $310.44 | −1.9% |
| 30% | $336.31 | −3.5% |
| 40% | $362.18 | −5.0% |
| 50% | $388.05 | −6.4% |
The figures used
| Figure | Amount | |
|---|---|---|
| Revenue, last 12 months | $1.6B | |
| EBITDA, last 12 months | $413M | 26.5% of revenue |
| Depreciation and amortization | $15.5M | |
| Capital spending | $92.1M | |
| Debt | $0 | |
| Cash | $1.4B | |
| Share price | $258.70 | on Oct 30, 2026 |
Fixed rules, the same as the interactive view's starting point: the shares are bought at today's price plus 30%, the company's debt is refinanced and fees take 2%. New debt is the least of 5.5× EBITDA, 65% of the price and the amount whose interest EBITDA covers 2 times, at 7.65% a year (SOFR 3.89% plus the high-yield B spread 3.26% plus 0.5%, rates of Oct 15, 2026). Revenue grows 1.2% in the first year — the company's own rate, held between −3% and +8% — fading to 3% by year 5; the EBITDA margin, depreciation and capital spending stay at today's share of revenue; working capital takes 10% of each year's added revenue; tax is 12% of profit after interest. Every dollar of free cash flow repays debt. After 5 years the buyer sells at today's multiple of EBITDA.
What a takeover could cost
Takeovers in its sector paid a median premium of 30% over the share price before the deal (the middle half 12% to 31%), according to the 14 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Astera Labs would cost about $336.31 a share, $61.9B for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 12% | $289.74 | $53.3B |
| Median | 30% | $336.31 | $61.9B |
| High end (a quarter paid more) | 31% | $338.90 | $62.4B |
The odds, from history
Historically 2.1% of companies with its figures were bought within a year (0.42× the average). Its figures put it in decile 1 of 10 (10 = the most likely to be bought). The odds come from a model of every merger proxy, tender-offer response and going-private statement filed on EDGAR since 2011, set against each company's size, margins, debt, cash flow and growth the year before.
Astera Labs' latest quarter
Astera Labs, Q3 2026: revenue $585M (+154% year over year), operating margin 30.6%, net earnings $183M, operating cash flow $179M. The chart follows the revenue to costs, profit and cash.
Questions
Is Astera Labs being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Astera Labs?
A leveraged buyout at today's price plus 30% ($336.31 a share) would return a loss of about 4% a year to a private-equity buyer over 5 years; no price, however low, gets a buyer to 20%. At $60.5B it would be larger than any buyout on record (the model flags anything over $60 billion), so this is a thought experiment more than a prospect.
What would a takeover of Astera Labs cost?
Takeovers in its sector paid a median premium of 30% over the share price before the deal (the middle half 12% to 31%), according to the 14 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Astera Labs would cost about $336.31 a share, $61.9B for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.